Novo Nordisk will pay $300 million upfront for global rights to Hengrui's HRS-1596. The deal could be worth up to $2.6 billion with milestones.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
